COMMUNIQUÉS West-GlobeNewswire

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
15/05/2026
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating [...]
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
15/05/2026
Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026 BASECAMP remains on track to complete enrollment in Q3 2026 The Company has initiated the TRAILHEAD [...]
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
15/05/2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended [...]
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
15/05/2026
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; [...]
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
15/05/2026
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of [...]
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
15/05/2026
Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in [...]
Initiation of buy-back programme
15/05/2026
ANNOUNCEMENT NO. 309 15 May 2026 Initiation of buy-back programme The Board of Directors of ChemoMetec A/S has decided to buy back own shares based on the authorisation granted at the Annual General Meeting on 9 October [...]
105,950 Orion Corporation A shares converted into B shares
15/05/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 MAY 2026 at 9.00 EEST 105,950 Orion Corporation A shares converted into B shares In accordance with [...]
Desert Hope Treatment Center Welcomes Alumni Coordinator Whose Recovery Journey Began in Its Program
15/05/2026
LAS VEGAS, May 14, 2026 (GLOBE NEWSWIRE) -- Desert Hope Treatment Center, a leading addiction treatment center in Las Vegas, has appointed Madot (“Maddie”) Gebreegziabher as Alumni Coordinator. In her role, Maddie leads [...]
BioSyent Declares Second Quarter 2026 Dividend
15/05/2026
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common [...]
Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition
15/05/2026
The report, led by the United Kingdom’s APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public [...]
BioSyent Releases Financial Results for First Quarter 2026
15/05/2026
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2026. Key highlights include: (CAD) Q1 [...]
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology [...]
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
14/05/2026
BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer [...]
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Aurix Product Exhibiting Strong Market Growth HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing [...]
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
14/05/2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical [...]
Precipio Announces Q1 2026 Financial Results
14/05/2026
Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc [...]
HEALIOS K.K. to Present at Jefferies Global Healthcare Conference
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference in New York City as [...]
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
14/05/2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

Pages